292 related articles for article (PubMed ID: 12878586)
21. The human complement system: assembly of the classical pathway C3 convertase.
Kerr MA
Biochem J; 1980 Jul; 189(1):173-81. PubMed ID: 6906228
[TBL] [Abstract][Full Text] [Related]
22. Complement inhibition at the level of C3 or C5: mechanistic reasons for ongoing terminal pathway activity.
Mannes M; Dopler A; Zolk O; Lang SJ; Halbgebauer R; Höchsmann B; Skerra A; Braun CK; Huber-Lang M; Schrezenmeier H; Schmidt CQ
Blood; 2021 Jan; 137(4):443-455. PubMed ID: 33507296
[TBL] [Abstract][Full Text] [Related]
23. Mouse complement component C4 is devoid of classical pathway C5 convertase subunit activity.
Ebanks RO; Isenman DE
Mol Immunol; 1996 Feb; 33(3):297-309. PubMed ID: 8649451
[TBL] [Abstract][Full Text] [Related]
24. Differences between the binding sites of the complement regulatory proteins DAF, CR1, and factor H on C3 convertases.
Pangburn MK
J Immunol; 1986 Mar; 136(6):2216-21. PubMed ID: 2419425
[TBL] [Abstract][Full Text] [Related]
25. The mechanism of action of decay-accelerating factor (DAF). DAF inhibits the assembly of C3 convertases by dissociating C2a and Bb.
Fujita T; Inoue T; Ogawa K; Iida K; Tamura N
J Exp Med; 1987 Nov; 166(5):1221-8. PubMed ID: 2445886
[TBL] [Abstract][Full Text] [Related]
26. Regulation and deregulation of the fluid-phase classical pathway C3 convertase.
Gigli I; Sorvillo J; Halbwachs-Mecarelli L
J Immunol; 1985 Jul; 135(1):440-4. PubMed ID: 3158705
[TBL] [Abstract][Full Text] [Related]
27. Structural Basis for the Function of Complement Component C4 within the Classical and Lectin Pathways of Complement.
Mortensen S; Kidmose RT; Petersen SV; Szilágyi Á; Prohászka Z; Andersen GR
J Immunol; 2015 Jun; 194(11):5488-96. PubMed ID: 25911760
[TBL] [Abstract][Full Text] [Related]
28. Binding and activation of C4 and C3 on the red cell surface by non-complement enzymes.
Kirschfink M; Borsos T
Mol Immunol; 1988 May; 25(5):505-12. PubMed ID: 3412332
[TBL] [Abstract][Full Text] [Related]
29. A single arginine to tryptophan interchange at beta-chain residue 458 of human complement component C4 accounts for the defect in classical pathway C5 convertase activity of allotype C4A6. Implications for the location of a C5 binding site in C4.
Ebanks RO; Jaikaran AS; Carroll MC; Anderson MJ; Campbell RD; Isenman DE
J Immunol; 1992 May; 148(9):2803-11. PubMed ID: 1573269
[TBL] [Abstract][Full Text] [Related]
30. Molecular basis of complement resistance of human melanoma cells expressing the C3-cleaving membrane protease p65.
Ollert MW; Kadlec JV; Petrella EC; Bredehorst R; Vogel CW
Cancer Res; 1993 Feb; 53(3):592-9. PubMed ID: 8425193
[TBL] [Abstract][Full Text] [Related]
31. Alternative pathway of complement: recruitment of precursor properdin by the labile C3/C5 convertase and the potentiation of the pathway.
Medicus RG; Götze O; Müller-Eberhard HJ
J Exp Med; 1976 Oct; 144(4):1076-93. PubMed ID: 978134
[TBL] [Abstract][Full Text] [Related]
32. The mechanism of activation of the alternative pathway of complement by cell-bound C4b.
Farries TC; Steuer KL; Atkinson JP
Mol Immunol; 1990 Nov; 27(11):1155-61. PubMed ID: 2247091
[TBL] [Abstract][Full Text] [Related]
33. Functional Characterization of Alternative and Classical Pathway C3/C5 Convertase Activity and Inhibition Using Purified Models.
Zwarthoff SA; Berends ETM; Mol S; Ruyken M; Aerts PC; Józsi M; de Haas CJC; Rooijakkers SHM; Gorham RD
Front Immunol; 2018; 9():1691. PubMed ID: 30083158
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes.
Medof ME; Kinoshita T; Nussenzweig V
J Exp Med; 1984 Nov; 160(5):1558-78. PubMed ID: 6238120
[TBL] [Abstract][Full Text] [Related]
35. Molecular interactions between MASP-2, C4, and C2 and their activation fragments leading to complement activation via the lectin pathway.
Wallis R; Dodds AW; Mitchell DA; Sim RB; Reid KB; Schwaeble WJ
J Biol Chem; 2007 Mar; 282(11):7844-51. PubMed ID: 17204478
[TBL] [Abstract][Full Text] [Related]
36. Purification and characterization of the C3 convertase of the classical pathway of human complement system by size exclusion high-performance liquid chromatography.
Nagasawa S; Kobayashi C; Maki-Suzuki T; Yamashita N; Koyama J
J Biochem; 1985 Feb; 97(2):493-9. PubMed ID: 3874204
[TBL] [Abstract][Full Text] [Related]
37. Participation of C3 and its ligands in complement activation.
Volanakis JE
Curr Top Microbiol Immunol; 1990; 153():1-21. PubMed ID: 2404692
[TBL] [Abstract][Full Text] [Related]
38. [Formation of classical C3 convertase during the alternative pathway of human complement activation].
Kozlov LV; Shibanova ED; Zinchenko AA
Biokhimiia; 1987 Apr; 52(4):660-6. PubMed ID: 3647798
[TBL] [Abstract][Full Text] [Related]
39. C3 convertase of human complement: enhanced formation and stability of the enzyme generated with nickel instead of magnesium.
Fishelson Z; Müller-Eberhard HJ
J Immunol; 1982 Dec; 129(6):2603-7. PubMed ID: 6923908
[TBL] [Abstract][Full Text] [Related]
40. C5 convertase of the alternative complement pathway: covalent linkage between two C3b molecules within the trimolecular complex enzyme.
Kinoshita T; Takata Y; Kozono H; Takeda J; Hong KS; Inoue K
J Immunol; 1988 Dec; 141(11):3895-901. PubMed ID: 3183384
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
